MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Exercise of Warrants and Total Voting Rights

RNS

RNS Number : 9295E
N4 Pharma PLC
14 February 2018
 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Exercise of Warrants and Total Voting Rights

The Company announces that it has received an exercise notice for the exercise of 394,328 warrants over ordinary shares of 0.4p each at an exercise price of 8.5 pence per warrant ("New Ordinary Shares"). Application has been made for admission of 394,328 New Ordinary Shares to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on 16 February 2018.

Following Admission, there will be a total of 87,723,751 ordinary shares in issue. Shareholders should use the figure of 87,723,751 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure and Transparency Rules.

 

Enquiries:

N4 Pharma

CEO, Nigel Theobald

 

Via Alma PR

Stockdale Securities

Tom Griffiths

 

Tel: +44(0)207 601 6100

Beaufort Securities

Elliot Hance

 

Tel: +44(0)207 382 8300

Alma PR

Josh Royston

Robyn Fisher

 

Tel: +44(0)778 090 1979

Tel: +44(0)754 070 6191

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGMZNDKGRZM